The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series
Open accessAbstract
WHAT IS KNOWN AND OBJECTIVE: Cannabidiol (CBD) is the main non-psychotropic component of the Cannabis sativa plant. REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of muscle atonia during REM sleep associated with nightmares and active behaviour during dreaming. We have described the effects of CBD in RBD symptoms in patients with Parkinson's disease. CASES SUMMARY: Four patients treated with CBD had prompt and substantial reduction in the frequency of RBD-related events without side effects. WHAT IS NEW AND CONCLUSION: This case series indicates that CBD is able to control the symptoms of RBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“CB1 receptors are found in many brain areas, including those directly related to the regulation of the sleep–wake cycle.(11) In animal models, the activation of CB1 receptors by anandamide, an endogenous cannabinoid, increased the duration of slow-wave and REM sleep and reducedwakefulness.”
BackgroundSchenck, C. H., Bundlie, S. R., & Mahowald, M. W. (1996) · Neurology · doi:10.1212/wnl.46.2.388 · Cited by 1,083
Self-citationSafety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1×
“Then, this hypothesis underscores the need for studies with larger therapeutic windows exploring the endocannabinoid system in regard to its neuroprotective potential, especially when we know that CBD is a safe, well-tolerated drug.(22) Before concluding, it is important to mention that this study is based on a small…”
BackgroundCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 1×
“Several studies have shown that CBD has a broad spectrum of action that includes hypnotic, antipsychotic, anxiolytic and neuroprotective properties.(1) There are few investigations about the effects ofCBDon the sleep– wake cycle; however, CBD 160 mg/day was shown to significantly increase the quality of sleep, with su…”
BackgroundLastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century
Claassen, D. O., Josephs, K. A., Ahlskog, J. E., Silber, M. H., Tippmann-Peikert, M., & Boeve, B. F. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7fac · Cited by 392
Boeve, B. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00072-8 · Cited by 366
Cannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355 · cited 1×
“Also, there was a significant improvementasmeasuredwithaglobalscale toassessPD(UnifiedParkinson’s Disease Rating Scale, UPDRS) and reports of clinical improvement in sleep.(6) Next, we started a parallel double-blind, placebo-controlled exploratory trial to assess the effects of CBD (at doses of 75 and 300 mg) on PD s…”
BackgroundSelf-citationLocalization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆
Moldrich, G., & Wenger, T. (2000) · Peptides · doi:10.1016/s0196-9781(00)00324-7 · Cited by 335
García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320
Cited by
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Cannabis, Cannabinoids, and Sleep: a Review of the Literature
Babson, K. A., Sottile, J., & Morabito, D. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0775-9 · Cited by 484
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365
Self-citationLöscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
Self-citationZuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294
Self-citationFraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-0015 · Cited by 241
Self-citationSholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
Peball, M., Krismer, F., Knaus, H., Djamshidian, A., Werkmann, M., Carbone, F., Ellmerer, P., Heim, B., Marini, K., Valent, D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25864 · Cited by 123
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder
de Almeida, C. M. O., Brito, M. M. C., Bosaipo, N. B., Pimentel, A. V., Tumas, V., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Eckeli, A. L. (2021) · Movement Disorders · doi:10.1002/mds.28577 · Cited by 70
“Considering a statistical power of 80% (1-β) and α of 5% and estimating a reduction of at least 50% of weekly behavior manifestations, it was defined that it would be necessary to include 16 patients in each group outcome.(6) We presented quantitative variables as mean and standard deviation and qualitative variables…”
BackgroundMethodInfluentialSelf-citationWeber, I., Zagona-Prizio, C., Sivesind, T. E., Adelman, M., Szeto, M. D., Liu, Y., Sillau, S. H., Bainbridge, J., Klawitter, J., Sempio, C., et al. (2024) · JMIR Dermatology · doi:10.2196/49965 · Cited by 7
Proserpio, P., Terzaghi, M., Manni, R., & Nobili, L. (2022) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.06.004 · Cited by 4
Metadata
- Authors
- Chagas, M. H. N., Eckeli, A. L., Zuardi, A. W., Pena-Pereira, M. A., Sobreira-Neto, M. A., Sobreira, E. T., Camilo, M. R., Bergamaschi, M. M., Schenck, C. H., Hallak, J. E. C., Tumas, V., & Crippa, J. A. S.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2014-05-21
- Volume
- 39
- Issue
- 5
- Pages
- 564-566
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W2032847771
- Cited by
- 253
- References
- 23
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.